{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0"},{"groupId":"OG001","value":"38.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"description":"Outpatient medical encounters included various sites of care: a) emergency room (ER) visits, b) hospital outpatient visits, c) home care visit, d) visit to lab, e) visit to doctor's office, f) other visits. Percentages were rounded off to the nearest single decimal place.","groups":[{"description":"Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.","id":"OG000","title":"Phase 3: Imetelstat Sodium"},{"description":"Imetelstat sodium-matching placebo administered IV, every 4 weeks (on a 28-day cycle), until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.","id":"OG001","title":"Phase 3: Placebo"}],"paramType":"NUMBER","populationDescription":"Phase 3: ITT Analysis Set included all participants randomized into the Phase 3 study.","reportingStatus":"POSTED","timeFrame":"Up to 3.7 years in Phase 3","title":"Phase 3: Medical Resource Utilization Assessed Based on Percentage of Participants With Outpatient Medical Encounters","type":"SECONDARY","unitOfMeasure":"percentage of participants"}